Thalidomide

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma MM ; : Results of 2 Phase III Studies MM-009, MM-010 ; and Subgroup Analysis of Patients with Impaired Renal Function. Donna Weber, Michael Wang, Christine Chen, Andrew Belch, Edward A. Stadtmauer, Ruben Niesvisky, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert D. Knight, Meletios Dimopoulos Time: 10: 30 AM7: 00 Location: Hall E1, Board #776-III Abstract No: 3547 Session Type: Poster Session Poster Session: Myeloma: Immumomodulatory-Based Therapies 10: 30 AM7: 00 ; Lenalidomide Revlimid ; + - Corticosteroids in Elderly Patients with Relapsed Refractory Multiple Myeloma. Donna E. Reece, Esther Masih-Khan, Christine Chen, Lisa Wang, Saima Dean, Suzanne Trudel, Joseph R. Mikhael, Vishal Kukreti, Robert Knight, Jerome Zeldis Time: 10: 30 AM7: 00 Location: Hall E1, Board #779-III Abstract No: 3550 Session Type: Poster Session Poster Session: Myeloma: Immumomodulatory-Based Therapies 10: 30 AM7: 00 ; Lenalidomide Revlimid ; , in Combination with Cyclophosphamide and Dexamethasone CRD ; Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients. Gareth J. Morgan, Stephen Schey, Ping Wu, M. Srikanth, Karen J. Phekoo, Matthew W. Jenner, Sharon Dines, Radovan Saso, Faith E. Davies Time: 10: 30 AM7: 00 Location: Hall E1, Board #784-III Abstract No: 3555 Session Type: Poster Session Poster Session: Myeloma: Immumomodulatory-Based Therapies 10: 30 AM7: 00 ; Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic Smoldering or Indolent ; Myeloma. Suzanne Hayman, Morie Gertz, Martha Lacy, Angela Dispenzieri, Rafael Fonseca, Susan Geyer, Shaji Kumar, Steven Zeldenrust, Stephen Russell, John Lust, Robert Kyle, Philip Greipp, Thomas Witzig, S. Vincent Rajkumar Time: 10: 30 AM7: 00 Location: Hall E1, Board #797-III Abstract No: 3568 Session Type: Poster Session Poster Session: Myeloma: Immumomodulatory-Based Therapies 10: 30 AM7: 00. Jauniaux et al., 1991a, b ; . End diastolic flow is usually absent from umbilical arteries until the 12th week of gestation and does not become detectable in all pregnancies until 15 weeks Den Ouden et al., 1990; Arduini and Rizzo, 1991 ; . The appearance of end diastolic flow is accompanied by a sharp decrease in umbilical artery PI. Abbreviations: CCLE, chronic cutaneous lupus erythematosus; LE, lupus; SCLE, subacute cutaneous LE; SLE, systemic LE. * Six patients patients 1, 9, 10, and 26 ; who took thalidomide for less than 1 month and whose clinical responses were unknown were excluded from this table. Patient 12 had diagnoses of both CCLE and LE profundus and was counted twice. Patient 16 had diagnoses of both SLE and LE profundus and was counted twice. Patient 11 discontinued thalidomide therapy after 1 month because of drug costs and then restarted 5 months later with an initial partial clinical response but unknown percentage of improvement. After excision and fixation of the heart, the positions of the needle electrodes relative to individual muscle layers could be verified. In 90% of all impalements, the very tip of the needles would perforate the endocardium, so that the most distal electrode pair was located subendocardially. The mean thickness of the left anterior wall was 9.2 0.8 mm.

Cantly higher in Fib hamsters aged 6 and 10 mo than in Fib hamsters aged 3 mo p 0.05 ; . On the other hand, the myocardial [I25I]MIBG uptake was significantly lower in BIO 53.58 hamsters aged 6 and 10 mo than in BIO 53.58 hamsters aged 3 mo p 0.01 ; . The myocardial NE concentration was not significantly different between BIO 53.58 and Fib hamsters aged 3 mo p 0.09 ; . The myocardial NE concentration was significantly lower in BIO 53.58 hamsters aged 6 and 10 mo than in age-matched Fib hamsters p 0.01 ; . The myocardial NE concentration was higher in Fib hamsters aged 6 and 10 mo than in Fib hamsters aged 3 mo p 0.07 and p 0.06, respectively ; . The myocardial NE concentration was signifi cantly lower in BIO 53.58 hamsters aged 6 and 10 mo than in BIO 53.58 hamsters aged 3 mo p 0.01 ; . The myocardial NE concentration was significantly lower in BIO 53.58 aged 10 mo than in BIO 53.58 hamsters aged 6 mo p 0.05 ; . The relationship between myocardial [I25I]MIBG uptake and myocardial NE concentration in BIO 53.58 hamsters is shown in Figure 1. The myocardial [I25I]MIBG uptake was signifi cantly correlated to myocardial NE concentration r 0.80: p 0.001; n 20 ; . Table 3 shows the findings of each group in the second study. The body weight was significantly lower in the CLZ- and VER-treated BIO 53.58 hamsters than in the untreated BIO 53.58 hamsters p 0.01 ; . The heart body weight ratio was significantly higher in the CLZ- and VER-treated BIO 53.58 hamsters than in the untreated BIO 53.58 hamsters p 0.05 ; . Pleural effusion and ascites were absent in all groups. Table 4 shows the myocardial [I25I]MIBG uptake, NE concentration and fibrosis ratio in the second study. The myocardial [I25I]MIBG uptake was significantly higher in the CLZ- and VER-treated BIO 53.58 hamsters than in the un treated BIO 53.58 hamsters p 0.05 and p 0.01, respec tively ; . On the other hand, the myocardial NE concentration was not different among these three groups p 0.05 ; . The myocardial fibrosis ratio was significantly lower in the CLZ- and VER-treated BIO 53.58 hamsters than in the un treated BIO 53.58 hamsters p 0.01; Table 4 and Fig. 2 ; . The relationship between myocardial [I25I]MIBG uptake and myo.

Topical NSAID diclofenac also, is not approved by the FDA, but has been studied in several randomized, controlled trials. Topical diclofenac was found to be more effective than placebo41, 42 and to provide equivalent relief compared with oral diclofenac43 for the treatment of knee osteoarthritis. This agent was found to be as effective as oral diclofenac for the relief of temporomandibular joint pain as well, without inducing adverse systemic effects.44 Also, signifigantly reduced pain intensity and minimal side effects have been reported for the treatment of osteoarthritis and LBP with the lidocaine patch 5% in 3 open-label pilot studies.45-47 A recent Geriatrics publication recommended the topical analgesics, lidocaine patch 5% and capsaicin as options for pain associated with rheumatologic illnesses in the elderly population.48 Other Investigational Analgesics The neurotoxin botulinum toxin type A BoNT A ; is reported to be efficacious for several disorders of involuntary muscle contraction and is being investigated as a novel treatment for pain associated with migraine and other types of chronic headaches.49 BoNT A is known to inhibit the release of acetylcholine at cholinergic synapses, which at the neuromuscular junction results in a flaccid paralysis; however, other newly discovered mechanisms of the toxin--for example, its effect on glutamate transmission, as well as the reduction of substance P and calcitonin gene-related peptide release--may be more relevant with respect to its analgesic effects. Several open-label studies and 3 placebo-controlled trials reported decreased migraine frequency and severity following BoNT A injection, with a small frequency of transient, minor side effects.49 BoNT A was found to be efficacious for the relief of chronic LBP, as well, in a randomized, placebo-controlled study of 31 patients.50 Thalidomide is also under investigation for the management of chronic pain. Pain Management for the Elderly: Opioid Pharmacotherapies The proven efficacy of opioids for the reduction of pain from several sources, including both acute cancer-related and chronic, noncancer-related pain, has encouraged the growing recognition that opioids are essential for the management of chronic pain.51 The potential risks of opioid use are serious but manageable, especially with the plethora of guidelines available from sources such as the FDA, Federation of State Medical Boards, and the American Pain Society.

Have started obtaining decubitus radiographs first to try to improve distention, especially in the proximal colon. As mentioned previously, proximal technical errors might be decreased with increased attention to the proximal colon by using more spot radiographs in more positions in an attempt to overcome redundancy and poor coating. The patients may need increased maneuvers such as more insufflation and more rotations to improve both distention and mucosal coating. While we have no data to determine if the aforementioned changes will make any difference in our technical errors, we have instituted the aforementioned changes in our performance of ACBE examinations. In conclusion, the majority of errors 82% ; for all polyps were technical, and the majority of all missed polyps 78% ; were in the proximal colon. These data suggest that radiologists might improve polyp detection rates at ACBE examinations by paying greater attention to technical aspects of an ACBE examination, especially in the proximal colon and thiamin. Lenalidomide Revlimid ; has only shown potential benefit in patients with one particular subtype of MDS Low- to Intermediate-1-risk MDS associated with a specific chromosome 5q ; deletion ; . Potential treatment alternatives for MDS may include: erythropoetin alfa Procrit ; , azacitidine Vidaza ; , thalidomide Thalomid ; and antithymocyte globulin Atgam ; . Allogeneic bone marrow transplant is the only hope for a cure for MDS, however not all patients are candidates for this procedure due to age limitations 65 years ; . Safety concerns with lenalidomide Revlimid ; include potential for birth defects, severe neutropenia thrombocytopenia, and increased risk of pulmonary embolism and deep venous thrombosis. There are ongoing trials that study lenalidomide Revlimid ; in a host of other conditions, which puts it at high risk for off-label use.

The clinical utility of thalidomide as front-line therapy continues to be supported. The Eastern Cooperative Oncology Group reported final results of the Phase III study comparing thalidomide plus dexamethasone thal-dex ; with dex alone in newly diagnosed patients Rajkumar et al ; . Results of the study showed a 63% response rate at 4 months with the oral combination regimen compared with 41% responding to dex alone. These data confirmed the results of the interim analysis, which were reported in 2004 at the ASCO Annual meeting, and demonstrate the utility of either regimen as an alternative to the and thioguanine.
S9922, A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin DCEP ; and G-CSF With or Without Thalidomide NSC #66847 ; as Salvage Therapy for Patients with Refractory Multiple Myeloma. Study Coordinators: Drs. M. Hussein and J. Weick. Permanent Closure effective 11 01 ; C19801, A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia ALL ; or Lymphoblastic Lymphoma LBL ; . Study Coordinators: Drs. S.E. Coutre, A.T. Stopek, D.R. Head and D.H. Boldt. Permanent Closure effective 09 12 01 ; E2998, A Phase III Study of Flt3 Ligand Flt3L ; NSC #696599 ; Therapy in Acute Myeloid Leukemia AML ; Patients in Remission. Southwest Oncology Group Study Coordinators: Drs. J. Godwin, D. Head, C. Willman and M. Slovak. Permanent Closure effective 10 01. Culated using the trapezoidal rule ; , the minimum postdose concentration Cmin ; , and the postdose Cmax. The changes from baseline to d 30 and d 90 in Cmin, Cavg, and Cmax were analyzed using an analysis of covariance with baseline value as the covariate and treatment group as the factor. Patients randomized to AA2500 50 mg d or 100 mg d ; may have had their dose changed at the d 60 visit. Those patients with a dose change will be analyzed at d 90 using the dose they received at the d 60 visit. Similar analyses were used for the change from baseline in sexual function, mood, and body composition as well as for the clinical laboratory parameters at d 30, 60, and 90. Treatment-emergent adverse events were compared using a Fisher's exact test. Skin irritation at d 30, 60, and 90 was analyzed using a Wilcoxon rank sum test. At d 30 and 90, the 50 mg d and 100 mg d AA2500 treatment groups were compared with T patch PK parameters, sexual function, body composition, and mood ; and placebo sexual function, body composition, and mood ; . For each comparison, including safety parameters, an -value of 0.05 was considered significant. The changes from baseline in sexual function, body composition, and mood were also analyzed for nonzero differences within each treatment group based on the adjusted least squares means from the analysis of covariance model. SAS version 6.12 SAS Institute, Inc., Cary, NC ; was used for all analyses. All data in tables are presented as means sd and thiotepa.
Prevalence of liver steatosis was 37, 9%. Values of transaminase above the elevated levels ALT, AST and or GGT ; were present in 13, 3% of the group with US liver steatosis, and this group was showed bigger grade of US liver steatosis Grade II: 44, 4%; Grade III: 22, 2% ; . The correlations the biochemical parameters in the subjects, grouped according to the presence or not of liver steatosis are illustrated in table I and II. Triglycerides, LDL, total cholesterol, GPT, hyperinsulinemic, HOMA and metabolic syndrome were significantly higher among patients US fatty liver. In rest parameters, including exercise and diet, the differences were not statiscally significant. Logistic regression selected metabolic syndrome and hyperinsulinemic as factors independently associated with fatty liver OR: 182% and OR: 4, 3% respectively. Manufacture of other Bianor Sp. z o. o. Bialystok ; plastic products dressing and dyeing of fur; manufacture of articles of fur forging, pressing, stamping and roll forming of metal De' Medici Europe KZF Krakw Sp. z o. o. Krakw and thiothixene.

Rabbit LBC cultures treated with 10 and 5 M thalidomide did not produce results significantly different from control values, measuring 14.9 5.4 and 3.0 13.7% increases from control fluorescence Fig. 2 ; . However, 25, 50, and 100 M thalidomide concentrations all produced significant levels of oxidative stress and differences in fluorescence. Cultures treated with 25 M thalidomide increased from control fluorescence by 26.7 6.0%. Both treatments of 50 and 100 M thalidomide resulted in increased fluorescence of 86.4 16.4 and 183.8 19.4% in rabbit LBC cultures. Comparisons between thalidomide treatments in rat and rabbit LBC cultures showed that significant differences in fluorescence were shown at the two highest concentrations, 50 and 100 M. Addition of PBN caused a decrease in ROS-induced DCF. C.R. PATIL AND S.B. BHISE chronic graft-versus-host disease. Biol Blood Marrow Transplant 1996; 2: 86-92. Kemper F. Thalidomide and congenital abnormality. Lancet 1962; 2: 836. Melin GW, Katzenstein M. The saga of thalidomide. N Eng J Med 1962; 267: 1238-43. Arlen RR, Wells PG. Inhibition of thalidomide teratogenicity by Acetyl salicylic acid: Evidence for PGH synthase catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J Pharmacol Exp Ther 1996; 277: 1649-58. Ochonisky S, Verroust J, Bastuji-Garin S. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-9. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical electrophysiological and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543-51. Wullf CH, Hoyer H, Asboe-Hansen G. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-80. Gunzler V. Thalidomide in human immunodeficiency virus HIV ; patients: a review of safety considerations. Drug Safety 1992; 7: 116-34. Koch HP. Thalidomide and congeners as anti-inflammatory agents. In: Ellis GP, West GP, editors. Progress in Medicinal Chemistry. 3rd ed. Elsevier Publications. 1985. p. 165242. 70. Willimas I, Weller IVD, Malin A, Anderson J, Waters MF. Thalidomide hypersensitivity in AIDS. Lancet 1991; 337: 4367. Pollard M. Thalidomide promotes metastasis of prostate adenocarcinoma cells PA-III ; in L-W rats. Cancer Lett 1996; 101: 21-4. Hosein S. A warning toxicity: Caution about thalidomide. Treatment Update 1995; 7: 59. Saphir A. Jekyll and Hyde: A new license for thalidomide? J Natl Cancer Instt 1997; 89: 1480-1. Corral LG, Haslett PA, Mullar GW. Differential cytokine moduaion and T- cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a1. J Immunol 1999; 163: 380-6 and thorazine.

There are at least 38 sites around the country testing thalidomide for hiv-related ulcers. Studies presented here at the 41st meeting of the american society of hematology ash ; , included use of thalidomide as a single agent and in combination with other chemotherapeutic agents and timolol and thalidomide. LA8 Description of policies and programs on HIV AIDS We have a commitment and process for dealing with employee health and all serious illness, including, but not specific to HIV AIDS. The process is the Medical Review Board MRB ; . A MRB involves the employee and his her leader supervisor working collaboratively to find solutions that benefit both the employee and the Company. In some cases, the situation is complex. The leader needs the help of other resources within the Company to learn of all available options, and to insure both consistent and fair treatment and compliance with employment law. Consultation with the Human Resources Business Partner is available when additional expertise is required. DOW SOUTH AFRICA HIV AIDS POLICY Given the special situation in South Africa, we have developed a regional policy, driven by the World Economic Forum Best Practice Road Map: Acknowledges the seriousness and implications of the HIV AIDS epidemic for Dow South Africa Southern Africa and its employees; 46.

There is no need for all of a child's care to be given at a comprehensive care centre and many centres have an excellent arrangement, which involves going to a patient's local haemophilia centre to discuss all the basic day-to-day problems such as treatment of acute episodes of bleeding, this is called `shared care'. If a patient lives a long way from a comprehensive care centre, it might only then be necessary for them to travel up to the centre a couple of times a year. Here a patient's progress can be reviewed and appropriate advice given by the comprehensive care centre to the haemophilia centre and ting. We conclude that the combination of thalidomide and dexamethasone represents an active salvage regimen for patients with refractory myeloma. If its activity is confirmed from randomized studies, it should be used as soon as resistance to high-dose dexamethasone-based regimens is observed. This combination may also be used for the in vivo 'purging' of patients with primary refractory myeloma who are otherwise eligible for high dose therapy. TheTD regimen is also being evaluated as primary treatment for patients with active myeloma and the preliminary results are very promising [13].

178. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, vanBuuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 12649. Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986; 1: 1215. Zylicz Z, Krajnik M. Codeine for pruritus in primary biliary cirrhosis. Lancet 1999; 353: 813. Juby LD, Wong VS, Losowsky MS. Buprenorphine and hepatic pruritus. Br J Clin Pract 1994; 48: 331. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind crossover randomized trial. Gastroenterology 1988; 94: 48893. Anwer MS, Kroker R, Hegner D. Inhibition of hepatic uptake of bile acids by rifamycins. Naunyn Schmiedebergs Arch Pharmacol 1978; 302: 1924. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1: 5746. Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975; 82: 31017. Carey JB. Lowering of serum bile acid concentrations and relief of pruritus in jaundiced patients fed a bile acid sequestering resin. J Lab Clin Med 1960; 56: 7978. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50: 32332. Sherlock S, Dooley J. Diseases of the Liver and Biliary System, 9th edn. Oxford, Blackwell Scientific, 1993. 189. Ahrens EH, Payne MA, Kunkel HG. Primary biliary cirrhosis. Medicine 1950; 29: 299364. Lloyd-Thomas HGL, Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 1952; ii: 128991. 191. Sherlock S. Diseases of the Liver and Biliary System, 6th edn. Oxford, Blackwell Scientific, 1981. 192. Welder AA, Robertson JW, Melchert RB. Toxic effects of anabolic-androgen steroids in primary rat hepatic cell cultures. J Pharmacol Toxicol Methods 1995; 33: 18795. Gurakar A, Caraceni P, Fagiuoli S, vanThiel DH. Androgenic anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Oklahoma State Med Assoc 1994; 87: 399404. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. New England J Medicine 1968; 279: 697700. Gilchrest BA, Rowe JW, Brown RS. Ultraviolet phototherapy of uremic pruritus: long-term results and possible mechanisms of action. Annals of Internal Medicine 1979; 91: 1721. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67: 2703. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. J Hematology 1993; 43: 3168. Thalidomide -[N-phthalmido]-glutarimide ; was synthesized in 1954, in what was then West Germany, by Chemie Grunenthal under the brand name of Conter gan and was subsequently licensed in 46 other countries worldwide, covering all continents. It is an odorless white crystalline compound with low solubility in water McBride, '77; Stirling et al., '97 ; . A number of pharmaceutical companies manufactured thalidomide in various concentrations under several trade names Stirling et al., '97 ; . Advertisements for the drug claimed that it was helpful in treating anxiety, insomnia, gastritis, and tension and that it was safe and harmless for pregnant women Lenz, '88 ; . Additionally, it was an effective antiemetic in pregnancy McBride, '77 ; . Thalidomide was first marketed in Germany in October 1957 as an effective, safe, inexpensive sedative, and production in that country reached 14.58 tons by 1960 Zwingenberger and Wendt, '96 ; . A liquid form was available for children, and some compounds were sold without prescriptions Stirling et al., '97 ; . Routine screening tests found thalidomide to be nontoxic in rodents, and therefore its potent teratogenicity in humans and higher mammals was not anticipated Brent and Holmes, '88 ; . In the early 1960s an increasing number of infants were born with hypoplastic limb defects Lenz, '85 ; . In fall 1961, Lenz, noting these congenital malformations in the German population, suggested a possible correlation with thalidomide taken during pregnancy. He reported his observations at meetings and in the medical literature Lenz, '61a, b, '62; Lenz and Knapp, '62 ; . Similar observations were made in England Smithells, '62 ; and Australia McBride, '61 ; . Within a few months of the initially reported cases, the drug was withdrawn from commercial sale by Grunenthal November 1961 ; , and 9 months later was taken off the market in Japan. It was withdrawn from Great Britain in December 1961 Kida, '87 ; . The potent teratogenicity appropriately suppressed other uses of thalidomide, such as for anti-inflammatory effects Somers, '60, Miller et al., '60 ; . The U.S. Food and Drug Administration FDA ; had not approved the drug for unrestricted use because of concerns primarily about possible peripheral neuropathy ; raised by Francis Kelsey, an FDA physician. Thus.
Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ 1998 Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon- adminstration. Cancer Res 58: 808 814 Drasdo N, Chiti Z, Owens DR, North RV 2002 Effect of darkness on inner retinal hypoxia in diabetes. Lancet 359: 22512253 Dvorak HF, Nagy JA, Dvorak JT, Dvorak 1988 Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. J Pathol 133: 95109 Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD 1996 A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 7: 491 496 Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, VillalonaCalero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK 1999 Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol 17: 10951104 Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J 2002 Phase I clinical trial of recombinant human ednostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 37723784 Egginton S, Zhou AL, Brown MD, Hudlicka O 2000 The role of pericytes in controlling angiogenesis in vivo. Adv Exp Med Biol 476: 8199 Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H, Hallberg B, Nordlander M, Cao Y 2003 Deletion of neuropeptide Y NPY ; 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 100: 6033 6038 Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD 1995 Extracellular pH distribution in human tumours. Intl J Hyperthermia 11: 211216 Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL 2000 Integrins v 3 and v 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60: 712721 Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ 2003 Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 536: 19 24 Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A 2002 Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13: 1029 1035 Facchiano F, Lentini A, Fogliano V, Mancarella S, Rossi C, Facchiano A, Capogrossi MC 2002 Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. J Pathol 161: 531541 Fett JW, Strydom DJ, Lubb RR, Adlerman EM, Bethune JL, Riordan JF, Vallee BL 1985 Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24: 5480 5486 Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marme D, Augustin HG 2003 Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 17211727 Fife CE, Buyukcakir C, Otto GH, Sheffield PJ, Warriner RA, Love TL, Mader J 2002 The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity. Curves. Although a few 'luthors attempted to take the problem into consideration Dhanoa and Le Du, 1982; Goodall and Sprevak, 1984 ; , standard procedures which can take into account temporal dependence are still required. We intend to address the problem of twice-standard-error curves tliro~~gh external validation. During the last 20 years, numerous studies have elaborated descriptive equations of the lactation curve. Most of them aimed at estimating the tokal lactation yield on the basis of a few measures Wood, 1974; Schaeffer and Burnside, 1976; Congleton and Everett, 1980 ; . Our study provides the means of predicting this total yield through an early estimate which is either the initial production or the yield during the 5th week of lactation. The agreenlent between obser\ ed and predicted cum~~lative yields can be ill~istr~~tedthe root mean scluarc error 721 by and 485 kg with IP and Y, as estimator, respectively ; . It was, at least on curves used to adjust the model, as good or better than in previous works which used several tests for prediction from 586 to 751 kg with four monthly tests ; Congleton and Everett, 1980 ; . However, the major aim of our work was to describe and to predict the evolution of yield, as in Wood 1974 ; or in Coodall altd Sprevak 1985 ; , in order to obtain reference curves which can be modulated, ill simulation models, by the effect of various factors such as health and feeding features Lescourret czt ill., 1994 ; . The final equation allowed a very accurate description of lactation curves for large ranges of shape and production level. First, Morant and Cnanasakthy's equation 1989 ; chosen to describe the inherent yield, was able to represent very different patterns of milk evolution, contrary to Wood's 1967 ; and Cobby and Le Du's 1978 ; equations. Moreover, contrary to that of Rook r3t ill. 1993 ; which showed and thalomid.

Side effects were responsible for discontinuation of thalidomide in 14 patients 28% ; and a dose reduction in 24 48% ; . The median maximum tolerated dose was 200 mg day range 100500 mg ; , although 32% of patients tolerated 400 mg day. There were no significant differences between the two groups for these parameters. In group TM, 17 patients 63% ; received three courses of oral melphalan and the other 10 37% ; received more than three courses; in four patients 11% ; , melphalan administration was delayed due to haematological toxicity. Side effects attributable to thalidomide were constipation 72% ; , somnolence 38% ; , fatigue 24% ; and. Warning: The use of an airline should be restricted to a confined space, and the operator should wear suitable protective clothing and eye protection. This method is unlikely to clean the Filter completely. To avoid a cumulative effect you should periodically obtain an Eminox Ltd Service Exchange Filter. Any attempt to clean the Filter with pressurised water or steam is likely to compact any residual ash within the Filter which cannot then be removed. An excessive amount of soot on the inlet surface could indicate that considerable heat may have been generated within the Filter. This could cause severe internal structural damage. Blackened patches or individual blackened cells on the outlet side of the Filter are further evidence. If in any doubt about internal damage you should obtain an Eminox Ltd Service Exchange Filter. References thalidomide confers a limited response rate 5% ; and modest disease-control rate 18% ; in advanced hcc patients.
Claimant's request for information, the Arthritis Foundation advised claimant to contact her physician, explaining that the Foundation had given claimant their "most up-to-date general information" but "[o]nly your physician with your full medical history can determine what is advisable for you." The only medical evidence regarding whether claimant is medically stationary is from Dr. Jacobson, claimant's attending physician. Dr. Jacobson apparently performed the January 2000 right knee surgery for which claimant's Own Motion claim was reopened. In addition, he followed her treatment after that surgery. In a March 15, 2001 medical report, Dr. Jacobson concluded that claimant was medically stationary as of the date of the report. Although he noted that "down the road, the arthritis has the potential of getting worse, " the potential of future worsening does not negate the finding of medically stationary status, as explained above. He further stated that claimant was "as good as she is going to be." Although indicating that he could continue to "fine tune" things and treat claimant as necessary, Dr. Jacobson does not indicate that this ongoing medical care will materially improve claimant's compensable condition. Dr. Jacobson's medical opinion is unrebutted. Moreover, as claimant's long time treating physician Dr. Jacobson was in the best position to express an opinion regarding claimant's medically stationary date. Based on this uncontroverted medical evidence, we find that claimant's condition was medically stationary on the date her claim was closed.1 Therefore, we conclude that SAIF's closure was proper. Accordingly, we affirm SAIF's April 6, 2001 Notice of Closure in its entirety. IT IS SO ORDERED. Entered at Salem, Oregon on August 6, 2001.